1. Scrip
  2. >>New Products

Roche’s Vabysmo Sees The Only Growth In RVO

 
• By Elizabeth Cairns

Sales of the Swiss group’s bispecific in retinal vein occlusion are forecast to increase out to 2030 as sales of Eylea and Lucentis fall.    

Roche

Retinal vein occlusion (RVO) is a minor indication for Roche Holding AG‘s Vabysmo (faricimab), which has just been approved for this use in Europe. But the angiopoietin-2 and VEGF bispecific has one thing its RVO rivals do not: sales that are forecast to rise.

Key Takeaways
  • Roche’s Vabysmo has been approved for retinal vein occlusion in Europe, its third and smallest indication.
  • It was noninferior to Eylea in trials but no better

The RVO market is currently dominated by Bayer AG‘s ocular behemoth Eylea (aflibercept), a VEGF inhibitor. But that drug’s sales in the disease, split between the German group and its partners Regeneron Pharmaceuticals, Inc. and Santen Pharmaceutical Co., Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Ophthalmology

Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED

 
• By Alaric DeArment

Results from the Phase III THRIVE trial in active thyroid eye disease had analysts calling veligrotug “best-in-class” as they anticipate results from THRIVE-2 in chronic TED later this year.

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

Aldeyra Readies Reproxalap For Dry Eye Refiling After Chamber Study Success

 
• By Mandy Jackson

The company said earlier this year that it would resubmit reproxalap for US FDA approval before the end of 2024 once it completed another Phase III trial and is eyeing both acute and chronic use.